Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

48.00 +0.64 (+1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 798,214
Open 46.95
Bid (Size) 46.00 (1)
Ask (Size) 48.52 (1)
Prev. Close 47.36
Today's Range 46.62 - 48.20
52wk Range 20.08 - 57.28
Shares Outstanding 34,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know
Via Benzinga
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights. 
Via Benzinga

Performance

YTD
-13.0%
-13.0%
1 Month
+1.1%
+1.1%
3 Month
-11.3%
-11.3%
6 Month
+3.9%
+3.9%
1 Year
+29.6%
+29.6%

More News

Read More
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Earnings Scheduled For May 1, 2025
Via Benzinga
An Overview of Tarsus Pharmaceuticals's Earnings
Via Benzinga
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Earnings Scheduled For February 25, 2025
Via Benzinga
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
Via Benzinga
Would Mark Minervini consider TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) a top stock pick?
Via Chartmill
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Why Mark Minervini may look into TARSUS PHARMACEUTICALS INC (NASDAQ:TARS)
Via Chartmill
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Earnings Scheduled For November 13, 2024
Via Benzinga
Earnings Outlook For Tarsus Pharmaceuticals
Via Benzinga
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run
Via Investor's Business Daily
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?
Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market
What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?
The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 48.00
When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 05/05/25 04:00 PM ET
What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 1.64B
How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?
Tarsus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.